We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Iterum Therapeutics PLC | NASDAQ:ITRM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -3.73% | 1.55 | 1.50 | 1.55 | 1.60 | 1.50 | 1.59 | 110,155 | 00:48:29 |
Data to be presented at IDWeek 2023 include:
Presentation Title: Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)Poster #: 2016Presenter: Steven I. Aronin, MDTime/Location: Saturday, October 14, 12:15 p.m. - 1:30 p.m.
Presentation Title: Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection ModelPoster #: 2568Presenter: Brian D. VanScoy, BSTime/Location: Saturday, October 14, 12:15 p.m. - 1:30 p.m.
Presentation Title: Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection ModelPoster #: 2569Presenter: Brian D. VanScoy, BSTime/Location: Saturday, October 14, 12:15 p.m. - 1:30 p.m.
These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Investor Contact:Judy MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
1 Year Iterum Therapeutics Chart |
1 Month Iterum Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions